Published in final edited form as:

J Perinat Med. 2009 ; 37(6): 637–650. doi:10.1515/JPM.2009.101.

Maternal Serum Adiponectin Multimers In Gestational Diabetes

Shali Mazaki-Tovi^{1,2}, Roberto Romero^{1,3,*}, Edi Vaisbuch^{1,2}, Offer Erez^{1,2}, Pooja Mittal^{1,2}, Tinnakorn Chaiworapongsa^{1,2}, Sun Kwon Kim¹, Percy Pacora¹, Lami Yeo^{1,2}, Francesca Gotsch¹, Zhong Dong¹, Bo Hyun Yoon⁴, Sonia S. Hassan^{1,2}, and Juan Pedro Kusanovic^{1,2}

¹Perinatology Research Branch, Intramural Division, NICHD/NIH/DHHS, Hutzel Women's Hospital, Bethesda, MD, and Detroit, MI

²Department of Obstetrics and Gynecology, Wayne State University/Hutzel Women's Hospital, Detroit, MI

³Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI ³Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USA

⁴Department of Obstetrics and Gynecology, Seoul National University, Seoul, Korea

Abstract

Objective—Adiponectin, an adipokine with profound insulin-sensitizing effect, consists of heterogeneous species of multimers. These oligomeric complexes circulate as low-molecular-weight (LMW) trimers, medium-molecular-weight (MMW) hexamers and high-molecular-weight (HMW) isoforms and can exert differential biological effects. The aims of this study were to determine whether there is a change in circulating adiponectin multimers in the presence of gestational diabetes mellitus (GDM), overweight/obesity or with a treatment with sulfonylurea or insulin in patients with GDM.

Study design—This cross-sectional study included women with: 1) normal pregnancy (n=149); and 2) patients with GDM (n=72). Thirty three patients with GDM were managed with diet alone. Among the others 39 diabetic patients, 17 were treated with Glyburide and 22 with insulin. The study population was further stratified by first trimester BMI (normal weight <25 kg/m² vs. overweight/obese ≥ 25 kg/m²). Serum adiponectin multimers (total, HMW, MMW and LMW) concentrations were determined by ELISA.

Results—1) The median maternal serum of total, HMW, MMW and LMW were lower in patients with GDM than in those with normal pregnancies (p<0.001 for all comparisons); 2) patients with GDM had a lower HMW/Total adiponectin ratio and a higher MMW/Total and LMW/Total adiponectin ratio than those with a normal pregnancy (p<0.001 for all comparisons); and 3) among GDM patients, there were no differences in the concentrations and relative distribution of adiponectin multimers between those who were managed with diet, and those who were treated with pharmacological agents.

Conclusion—1) GDM is characterized by a distinctive pattern of concentrations and relative distribution of adiponectin multimers akin to Type-2 diabetes mellitus; 2) dysregulation of adiponectin multimeres can provide a mechanistic basis for the association between adiposity and GDM.

*Correspondence: Roberto Romero, MD Perinatology Research Branch, Intramural Division, NICHD/NIH/ DHHS, Hutzel Women's Hospital-Box No. 4, 3990 John R, Detroit, MI 48201 USA. Telephone (313) 993-2700, Fax: (313) 993-2694, prbchiefstaff@med.wayne.edu.

Keywords

Adipokines; Pregnancy; High-molecular-weight (HMW) adiponectin; Medium-molecular-weight (MMW) adiponectin; Low-molecular-weight (LMW) adiponectin; BMI; Gestational Diabetes; Diabetes; Overweight; Obesity

Introduction

Gestational diabetes mellitus (GDM), defined as a carbohydrate intolerance of varying severity with onset or first recognition during pregnancy [6, 42, 91, 102], affects 1–10% of all pregnancies [4, 5, 12, 24, 33, 67]. Several features of GDM make this common complication of pregnancy of special importance: 1) it is associated with an increased rate of short-term complications for the mother (e.g. cesarean section, and preeclampsia) [54, 70, 119, 129], the fetus (e.g. macrosomia, perinatal mortality) [122, 127], and the neonate (e.g. brachial plexus injury, hypoglycemia) [54, 55, 108, 120, 122, 127, 129, 148]; 2) weight reduction, exercise [19, 56], oral hypoglycemic agents and insulin [28, 68, 69, 121, 140] improve metabolic indices and reduce the rate of maternal, fetal and neonatal complications; 3) GDM is associated with long term morbidity and mortality for the mothers (Type-2 diabetes mellitus, cardiovascular disease) [2, 14, 20, 21, 32, 45, 60, 63, 109, 124]; and their infants (childhood obesity, metabolic syndrome) [7, 17, 30, 110] and 4) the prevalence of this metabolic complication is constantly increasing. [36, 143]

Recently, adipose tissue has emerged as an important endocrine organ via the production of adipokines. Furthermore, dysregulation of adipokine production and/or secretion has been implicated in Type-2 DM. Indeed, polymorphisms of several adipokines such as adiponectin [38, 44, 53, 71, 90, 96, 131], resistin [89, 104], visfatin [153], and leptin receptor [123] are associated with insulin resistance and Type-2 DM. Moreover, compared to non-diabetic individuals, patients with Type-2 DM have higher circulating concentrations of resistin [41, 88, 151], TNF- α [31, 92], RBP-4 [25, 150] and CRP [37, 111], as well as lower concentrations of adiponectin [51, 61, 112, 145]. These findings laid the groundwork for the hypothesis that perturbation of adipokine homeostasis has also a role in the pathophysiology of gestational diabetes.

Adiponectin, an adipokine produced exclusively and abundantly by adipocytes, is the most abundant gene (*AMP1*) product of adipose tissue [52, 74, 94, 125], and circulates at high concentrations in the plasma [59]. Unlike other adipokines, adiponectin concentrations are negatively correlated with adiposity [8, 52], suggesting that adipose tissue exerts a negative feedback on adiponectin production and/or secretion. Adiponectin has insulin sensitizing [13, 26, 40, 75, 98, 135, 149] and anti-inflammatory [126] properties, thus providing a mechanistic molecular basis for the association between an excess fat depot and obesity-related complication including Type-2 DM. Adiponectin is secreted from adipocytes and circulates in the plasma in distinct forms: 1) low-molecular-weight (LMW) trimers; 2) medium-molecular-weight (MMW) hexamers; and 3) high-molecular-weight (HMW) oligomers (12 to 18 subunits) [9, 16, 105, 138, 139, 144]. A growing body of evidence suggests that the different isoforms exert differential biological effects [9, 16, 64, 105, 106, 144]. Specifically, the anti-diabetogenic properties of adiponectin have been attributed to the HMW isoforms [11, 39, 47, 58, 64, 95, 106, 133, 136, 144].

Data regarding circulating maternal adiponectin multimers concentrations in human pregnancy are limited [23, 35, 77, 103, 115, 116, 132]. Indeed, only one study has reported the concentration of HMW adiponectin in patients with GDM. To date there are no reports concerning the concentrations and relative distribution of MMW or LMW. Moreover, there

are no data regarding the relationship between overweight/obesity and adiponectin multimers in patients with GDM. Thus, the aims of this study were to determine whether: 1) there is a change in adiponectin multimers concentrations in the presence of GDM or overweight/obesity; and 2) treatment with a sulfonylurea (Glyburide) or insulin is associated with a change in the concentrations of adiponectin and its multimers.

Materials and methods

Study groups and inclusion criteria

A cross-sectional study was conducted including patients in the following groups: 1) normal pregnant women (n=149); and 2) patients with GDM (n=72). The study population was further stratified by first trimester BMI (normal weight 18.5–24.9 kg/m² vs. overweight/obese ≥ 25 kg/m²).

Maternal serum and clinical data were obtained from our bank of biological samples and clinical databases. Many of these samples have been previously employed to study the biology of inflammation, angiogenesis regulation, and growth factor concentrations in normal pregnant women and in those with pregnancy complications.

Written informed consent was obtained from all participants after approval by the Institutional Review Boards of the Sotero del Rio Hospital (Santiago, Chile), Wayne State University (Detroit, Michigan, USA) and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD; Bethesda, Maryland, USA).

Clinical Definitions

The inclusion criteria for normal pregnant women were: singleton gestation, no prior diabetes mellitus, no maternal or fetal complications during pregnancy, normal plasma glucose concentrations in the first trimester, normal oral glucose challenge test, and delivery at term of a healthy neonate with a birthweight above the 10th percentile for gestational age.

All patients were screened for GDM with a 1-hour, 50-g oral glucose challenge test. Pregnant women with plasma glucose concentrations ≥ 135 mg/dL at 1 hour underwent a 100-g oral glucose tolerance test (OGTT). Women with two or more abnormal plasma glucose values were given a diagnosis of GDM [2, 22]. Patients with gestational diabetes were excluded from the study if they had pregestational diabetes mellitus, collagen vascular diseases, inflammatory bowel disease and chronic inflammatory conditions, or if they were using corticosteroids.

Maternal assessment and treatment of patients with gestational diabetes

All women diagnosed with GDM were given nutritional instructions for three meals and four snacks daily and individualized dietary advice from a qualified dietitian. Compliance with the dietary regimen was evaluated weekly during visits to the high-risk clinic. The diets were designed to provide 25 kcal per kilogram of body weight for obese women and 35 kcal per kilogram for lean women, with 40 to 45 percent of the calories from carbohydrates [2, 3].

A nurse educator instructed the women in how to measure blood glucose with a glucometer. The patients were asked to measure capillary blood glucose four times daily: after an overnight fast, and two hours after each meal [68]. The goals of treatment were a fasting blood glucose concentration of 60 to 90 mg/dL and a postprandial blood glucose concentration of less than 120 mg/dL [50]. If the blood glucose values of the patient treated with diet did not meet the goals for a two-week period the patient received a starting dose of

2.5 mg Glyburide orally in the morning. A physician evaluated the blood glucose values at each visit, and increased the Glyburide dose as needed to meet these goals. The dose of Glyburide was increased the following week by 2.5 mg and thereafter by 5 mg weekly up to a total of 20 mg daily when necessary [66]. If the blood glucose values of a woman treated with the maximal dose of Glyburide did not meet the goals for a two-week period, the treatment was switched to insulin therapy. The starting dose for insulin was 0.7 unit per kilogram of actual body weight at admission, given subcutaneously three times daily and increased weekly as necessary [68].

The BMI was calculated according to the formula: weight (kg)/height (m²). Normal weight women were defined as those with BMI of 18.5–24.9 kg/m² according to the definitions of the World Health Organization (WHO)[1]. Pregnant women were classified by their first trimester BMI into two groups: normal weight and overweight/obese (BMI ≥ 25 kg/m²).

Maternal blood samples were collected with a vacutainer directly into tubes. Samples were centrifuged and the sera were stored at –80°C until analysis. Sensitive enzyme-linked immunoassays were used to determine the concentrations of adiponectin multimeric forms in maternal serum. Immunoassays were purchased from ALPCO Diagnostics (Salem, NH, USA). The assays were run according to the manufacturer's recommendations. To detect HMW adiponectin, serum samples were pretreated with a specific protease that selectively digested MMW and LMW adiponectin. We were also able to determine the combined HMW and MMW adiponectin concentrations by pretreating the samples with a protease that specifically digested LMW adiponectin. Maternal serum samples were assayed directly to determine total adiponectin concentrations. Briefly, untreated and pretreated maternal serum samples were incubated in duplicate wells of the micro titer plates, which had been pre-coated with a monoclonal antibody specific for adiponectin. During this incubation any adiponectin present in the standards and untreated or pretreated maternal serum samples was bound by the immobilized antibodies. After repeated washing and aspiration to remove all unbound substances, an enzyme-linked polyclonal antibody specific for adiponectin was added to the wells. Unbound materials were removed with repeated washing and a substrate solution was added to the wells and color developed in proportion to the amount of adiponectin bound in the initial step. The color development was stopped with the addition of an acid solution and the intensity of color was read using a programmable spectrophotometer (SpectraMax M2, Molecular Devices, Sunnyvale, CA, USA). The concentration of adiponectin in untreated and treated maternal serum samples was determined by interpolation from individual standard curves composed of human adiponectin. Total, HMW, and HMW-MMW adiponectin concentrations were derived directly from the assay plates. MMW adiponectin concentrations were obtained by subtracting the HMW adiponectin value from the combined HMW-MMW value. Finally, the LMW adiponectin value was computed by subtracting HMW and MMW adiponectin values from the total adiponectin values. The calculated inter- and intra-assay coefficients of variation for adiponectin multimers immunoassays in our laboratory were 2.2% and 4.2%, respectively. The sensitivity was calculated to be 0.04 ng/ml.

Statistical analysis

Normality of data distribution was tested using the Shapiro-Wilk or Kolmogorov-Smirnov tests. Since serum multimeric adiponectin isoforms concentrations were not normally distributed, Mann-Whitney U test were used for comparisons of continuous variables. Kruskal–Wallis test was used for the comparison of normal pregnant women patients with diabetic patients with and without pharmacologic treatment, as well as for the comparison between normal weight and overweight pregnant women with and without GDM. Comparison of proportions was performed by Chi-square and Fisher's exact tests. Multiple linear regression analysis was used to determine which factors were significantly and

independently associated with maternal serum adiponectin isoforms as well as their relative distribution (after log transformation). The following parameters were included in the model: maternal age, parity, gestational age at sampling, gestational age at delivery, birth weight, first trimester BMI, difference in BMI between first trimester and blood sampling, and the presence of GDM. A p value <0.05 was considered statistically significant. Analysis was performed with SPSS, version 14 (SPSS Inc., Chicago, IL, USA).

Results

Table 1 displays the demographic and clinical characteristics of women with a normal pregnancy and those with GDM. Among patients with GDM, 33/72 were treated with diet alone. Among the other 39 diabetic patients, 17 were treated with Glyburide and 22 with insulin. As expected, patients with GDM had a higher first and third trimester BMI and larger neonates. There were no significant differences in maternal age, gestational age at blood sampling, gestational age at delivery and the difference in BMI between patients with a normal pregnancy and those with GDM (Table 1). Table 2 displays the demographic and clinical characteristics of the study population according to BMI. There were no significant differences in gestational age at blood sampling, gestational age at delivery and neonatal birthweight between normal weight and overweight/obese women in both groups (Table 2).

Adiponectin multimers concentrations and their relative distribution in GDM vs. normal pregnancy (non-GDM)

The median maternal serum concentration of total adiponectin was lower in patients with GDM than those with a normal pregnancy (median: 3,022 ng/mL, interquartile range [IQR] 2,102–4,204 vs. 6,019 ng/mL, IQR 4,596–8,256; $p<0.001$, Figure 1). Similarly, patients with GDM had a lower median serum concentration of HMW (1,203 ng/mL, IQR 593–1,800 vs. 3,297 ng/mL, IQR 2,187–4,657; $p<0.001$, Figure 1), MMW (881 ng/mL, IQR 639–1,259 vs. 1,394 ng/mL, IQR 993–1,839; $p<0.001$, Figure 1), and LMW adiponectin (968 ng/mL, IQR 782–1,218 vs. 1,236 ng/mL, IQR 818–1,724; $p<0.001$, Figure 1) than those with a normal pregnancy.

The median maternal HMW/Total adiponectin ratio was lower in patients with GDM than those with a normal pregnancy (0.37, IQR 0.27–0.45 vs. 0.54, IQR 0.47–0.62; $p<0.001$, Figure 2). In contrast, patients with GDM had a higher median MMW/Total adiponectin ratio (0.30, IQR 0.26–0.35 vs. 0.23, IQR 0.16–0.29; $p<0.001$, Figure 2), and a higher LMW/Total adiponectin ratio (0.32, IQR 0.25–0.39 vs. 0.21, IQR 0.15–0.28; $p<0.001$, Figure 2) than those with a normal pregnancy.

Adiponectin multimers concentrations and their relative distribution in GDM: normal weight vs. overweight/obesity

Among patients with GDM, women with normal weight and those with overweight/obesity did not differ in the median serum concentration of total adiponectin (3,731 ng/mL, IQR 2,218–5,809 vs. 2,848 ng/mL, IQR 2,070–4,092; respectively; $p=0.13$, Figure 3A), HMW adiponectin (1,315 ng/mL, IQR 679–3,239 vs. 1,168 ng/mL, IQR 570–1,645; respectively; $p=0.12$, Figure 3B), MMW adiponectin (1,071 ng/mL, IQR 650–1,271 vs. 858 ng/mL, IQR 625–1,218; respectively; $p=0.21$, Figure 3C), and LMW adiponectin (1,001 ng/mL, IQR 746–1,291 vs. 951 ng/mL, IQR 785–1,218; respectively; $p=0.97$, Figure 3D).

Similar to women with a normal pregnancy, among patients with GDM, patients with normal weight and those with overweight/obesity had a comparable median ratio of HMW/Total adiponectin (0.39, IQR 0.29–0.52 vs. 0.36, IQR 0.27–0.43; respectively; $p=0.1$, Figure 4A), MMW/Total adiponectin (0.30, IQR 0.21–0.36 vs. 0.30, IQR 0.27–0.35; $p=0.5$, Figure

4B), and LMW/Total adiponectin (0.29, IQR 0.17–0.38 vs. 0.33, IQR 0.28–0.33; $p=0.2$, Figure 4C).

Adiponectin multimers concentrations and their relative distribution in normal weight pregnant women: normal pregnancy (non-GDM) vs. GDM

Among patients with a normal weight, women with a normal pregnancy had a higher median serum concentration of total (6,987 ng/mL, IQR 5,051–8,713 vs. 3,731 ng/mL, IQR 2,218–5,809; $p<0.001$, Figure 3A), HMW (3,916 ng/mL, IQR 2,536–5,169 vs. 1,315 ng/mL, IQR 679–3,239; $p<0.001$, Figure 3B), MMW (1,446 ng/mL, IQR 1,021–1,914 vs. 1,071 ng/mL, IQR 650–1,271; $p=0.005$, Figure 3C) and LMW adiponectin (1,236 ng/mL, IQR 916–2,052 vs. 1,001 ng/mL, IQR 746–1,291; $p=0.01$, Figure 3D) than those with GDM.

Among patients with a normal weight, women with a normal pregnancy had a higher HMW/Total adiponectin ratio than those with GDM (0.55, IQR 0.49–0.63 vs. 0.39, IQR 0.29–0.52; $p<0.001$, Figure 4A). In contrast, MMW/Total ratio (0.23, IQR 0.16–0.28 vs. 0.30, IQR 0.21–0.36; $p=0.007$, Figure 4B) and LMW/Total adiponectin ratio (0.21, IQR 0.15–0.28 vs. 0.29, IQR 0.17–0.38 $p=0.013$, Figure 4C) were lower in women with a normal pregnancy than those with GDM.

Adiponectin multimers concentrations and their relative distribution in overweight/obese pregnant women: normal pregnancy (non-GDM) vs. GDM

Among patients with overweight/obesity, women with a normal pregnancy had a higher median serum concentration of total (5,207 ng/mL, IQR 4,291–7,095 vs. 2,848 ng/mL, IQR 2,070–4,092; $p<0.001$, Figure 3A), HMW (2,733 ng/mL, IQR 2,118–3,733 vs. 1,168 ng/mL, IQR 570–1,645; $p<0.001$, Figure 3B), MMW (1,330 ng/mL, IQR 788–1,683 vs. 858 ng/mL, IQR 625–1,218; $p<0.001$, Figure 3C), and LMW adiponectin (1,237 ng/mL, IQR 813–1,649 vs. 951 ng/mL, IQR 785–1,218; $p=0.02$, Figure 3D) than those with GDM.

Among patients with overweight/obesity, women with a normal pregnancy had a higher HMW/Total adiponectin ratio than those with GDM (0.54, IQR 0.45–0.61 vs. 0.36, IQR 0.27–0.43; $p<0.001$, Figure 4A). In contrast, MMW/Total ratio (0.23, IQR 0.16–0.29 vs. 0.30, IQR 0.27–0.35; $p<0.001$, Figure 4B) and LMW/Total adiponectin ratio (0.21, IQR 0.15–0.28 vs. 0.29, IQR 0.17–0.38; $p=0.013$, Figure 4C) were lower in overweight/obese women with a normal pregnancy than those with GDM.

Adiponectin multimers concentrations and their relative distribution in patients with GDM: the effect of pharmacologic treatment

Patients with GDM who were managed with diet and those treated with a pharmacologic agent (Glyburide or insulin) had comparable concentrations of total adiponectin (2,811 ng/mL, IQR 2,077–3,874 vs. 3,454 ng/mL, IQR 2,130–4,613; respectively; $p=0.2$). Similarly, median maternal serum concentrations of HMW, MMW and LMW adiponectin did not differ significantly between the two groups. The relative distribution of adiponectin isoforms was also comparable between the two groups. Similarly, there were no differences in the concentrations and relative distribution of adiponectin multimers between patients who were treated with Glyburide and those who were treated with insulin.

Multiple regression analysis was employed to examine the contribution of the presence of GDM on the serum concentration of adiponectin isoforms, while adjusting for maternal age, maternal BMI (normal weight vs. overweight/obese), the difference in BMI between the third and the first trimester, gestational age at blood sampling, and birthweight. The final regression model suggested that the presence of GDM and first trimester BMI were independently associated with decreased maternal serum total adiponectin ($p<0.001$ and

0.031, respectively), and HMW adiponectin concentrations ($p < 0.001$ and 0.009, respectively), as well as with decreased HMW/Total adiponectin ratio ($p < 0.001$ and 0.02, respectively).

Discussion

Principal findings of the study

1) The median maternal serum of total, HMW, MMW and LMW were lower in patients with GDM than in those with a normal pregnancy; 2) patients with GDM had a lower median HMW/Total adiponectin ratio and a higher MMW/Total and LMW/Total adiponectin ratio than those with a normal pregnancy; 3) among patients with GDM, median maternal serum concentrations of adiponectin multimers and their relative distribution did not differ between women with normal weight and those with overweight/obesity; 4) the presence of GDM was independently associated with low maternal serum of total and HMW adiponectin concentration as well as with decreased Total adiponectin, HMW adiponectin and HMW/Total adiponectin ratio; and 5) among GDM patients, there were no differences in the concentrations and relative distribution of adiponectin multimers between patients who were managed with diet, and those who were treated with pharmacological agents (Glyburide or insulin).

The role of adiponectin in obesity-related complications of pregnancy

Recently, adipokines have been implicated in physiologic adaptation of normal and complication of pregnancy [65, 77–86, 99–101, 141]. Indeed, the unique properties of adiponectin have prompted many investigators to explore the role of maternal circulating adiponectin in the metabolic adaptations occurring during human pregnancy [23, 82, 87], as well as in obesity-related complications of pregnancy such as GDM [62, 114, 134, 147] and preeclampsia [27, 29, 48, 49, 57, 73, 97, 113]. Indeed, normal pregnancy is associated with alterations in maternal circulating adiponectin [80, 82, 84, 128] and with changes in the relative distribution of its isoforms [23, 77, 115, 116]. In addition, even in the presence of a normal pregnancy, overweight pregnant women have a lower adiponectin concentration than those with a normal weight [43]. Moreover, low concentrations of adiponectin in the first or early second trimester is an independent risk factor for the development of GDM. Indeed, maternal adiponectin concentration $6.4 \mu\text{g/mL}$ at 13 weeks of gestation is associated with a 4.6-fold increased risk to develop GDM later in pregnancy [146], suggesting a causal relationship between low circulating adiponectin and GDM. Consistent with this finding, GDM is characterized by a low circulating concentrations of adiponectin [10, 62, 114, 117, 118, 134, 137, 147]. Collectively, a growing body of evidence points to a key role of adiponectin in the pathophysiology of both Type 2 DM and GDM.

An asymmetrical decrease in adiponectin multimers concentrations and alteration in their relative distribution are features of gestational diabetes

The findings of the present study characterize GDM as a condition in which there is a decrease in the maternal serum concentrations of all adiponectin multimers. In addition, there is a concomitant decrease in the HMW/Total adiponectin ratio and increases in MMW/Total as well as LMW/Total adiponectin ratios in patients with GDM. These findings are novel. Only one study has reported the concentrations of HMW adiponectin in patients with GDM [115]. The lower median maternal serum HMW concentration and HMW/Total adiponectin ratio in patients with GDM than those with a normal pregnancy, reported herein, are in agreement with the findings of Retnakaran et al. [115]. The present report extends these observations by demonstrating that the maternal concentrations of all adiponectin isoforms are decreased and that MMW/Total and LMW/Total ratios are increased in patients with GDM. Despite the fact that the decrease in adiponectin multimers was across the board, only

HMW/Total adiponectin ratio was lower in these patients compared with normal pregnant women, indicating that the decrease in HMW adiponectin was far more significant than the reduction in the concentrations of MMW or LMW isoforms. Indeed, MMW/Total adiponectin and LMW/Total adiponectin ratios were higher in patients with GDM than in those with a normal pregnancy. In conclusion, the results of this study clearly reveal that the low concentration of adiponectin in patients with GDM should be attributed to an accentuated decrease in HMW adiponectin.

Why is gestational diabetes associated with a disparate decrease of adiponectin multimeric complexes and their relative concentrations?

The findings regarding the asymmetrical decrease in adiponectin multimers and their relative concentrations reported herein support the emerging concept that the anti-diabetic effect of adiponectin may be mediated by the HMW isoforms. The cross sectional nature of the present study limits our ability to infer a causal relationship between adiponectin and GDM; however, the robust association of low circulating total and HMW adiponectin with states of insulin resistance has raised the possibility that there may be a cause and effect relationship between adiponectin and both Type 2 DM and GDM. Several lines of evidence suggest a causal linkage between the two: 1) treatment of adipose like cell lines (3T3-L1 cells) with peroxisome proliferator-activated receptor- γ agonist (Thiazolidinediones) results in increased adiponectin expression [76]; 2) *in vivo*, exposure of normal or obese mice to adiponectin increases insulin sensitivity [13, 40, 149]; 3) mutations in the adiponectin gene that result in failure to form HMW adiponectin (e.g. G84R and G90S) are associated with Type-2 DM and low adiponectin concentrations [144]. Similarly, polymorphisms in the adiponectin gene increase susceptibility to develop metabolic syndrome and Type-2 DM [38, 44, 46, 53, 71, 90, 96, 131] [142]; 4) low adiponectin concentrations confer an increased risk for the development of Type-2 DM even in the absence of any other biomarkers of impaired glucose metabolism [72, 130].

In conclusion, the findings reported herein define dysregulation of adipose tissue as a feature of GDM. It is tempting to postulate that the decrease in adiponectin multimeric complexes concentrations and their relative distribution can lead to modulation of adiponectin effect on target tissues (i.e muscles, liver, adipose tissue), thus providing a mechanistic basis to GDM.

Gestational diabetes and overweight/obesity – an ominous metabolic combination

The finding that adiponectin multimers and their relative concentrations are comparable between normal weight and overweight/obese patients with GDM is novel. The negative association between circulating adiponectin and excess adipose tissue accrual is well established [8, 77]. However, while overweight/obesity and weight gain usually mitigates adiponectin concentrations, we found no significant change in the concentrations of adiponectin multimers between normal weight and overweight/obese patients in the presence of GDM. Thus, it can be concluded that the effect of obesity on the quantitative and qualitative alterations in adiponectin multimers in obese pregnant women is overwhelmed by the presence of GDM. The fact that the median maternal serum concentrations of all adiponectin multimers were lower in overweight/obese patients with GDM than in overweight/obese individuals with a normal pregnancy further supports this hypothesis. Of interest, among overweight/obese subjects, the decrease in HMW adiponectin was disproportionate in patients with GDM as indicated by a lower median HMW/Total adiponectin ratio in patients with GDM than that of those with a normal pregnancy and higher median MMW/Total and LMW/Total adiponectin ratios.

Previous reports demonstrate that higher order adiponectin multimers do not interconvert in the circulation. Thus, the quantitative and qualitative changes in adiponectin multimers

reported herein must be attributed to altered production/secretion by adipocytes. Hence, it can be concluded that GDM is characterized by adipose tissue dysfunction as manifested by dysregulation of circulating adiponectin multimers. This finding may have clinical implications since manipulation of adiponectin concentrations and the relative distribution of its multimeric complexes opens new avenues for the treatment of Type 2 DM, as well as GDM.

Diet, sulfonylurea and insulin and adiponectin multimers concentrations and their abundance

There was no difference in the concentrations of adiponectin isoforms or their relative distribution between patients who were managed with diet and those who were treated with Glyburide or insulin. Similarly, patients treated with Glyburide and those treated with insulin had comparable concentrations of adiponectin multimers. These findings are novel. Indeed, there are no reports concerning the effect of sulfonylurea exposure on adiponectin concentrations during pregnancy; thus, the present study is the first to compare circulating adiponectin and adiponectin multimers in pregnant women with and without sulfonylurea treatment. The literature regarding the effect of insulin on adiponectin is controversial. Insulin's inhibitory effect on adiponectin gene expression has been demonstrated *in vitro* [34]. In accordance with this finding, a 10–20% reduction in adiponectin concentrations was reported in several hyperinsulinemic-euglycemic clamp studies in lean humans [18, 93, 152]. In contrast, other investigators found no effect of insulin on circulating adiponectin [107]. Importantly, contradictory reports concerning the effect of insulin on adiponectin multimers have been published. Selective decreases in HMW [11] as well as no changes in circulating concentrations of this isoforms [15] were reported. A possible explanation for the lack of insulin effect on adiponectin concentrations is that the inhibitory effect of insulin on adiponectin is not dose depended. In other words, once insulin reaches a certain concentration it cannot exert any additional inhibitory effect on adiponectin [15]. Since hyperinsulinemia is a characteristic of GDM, supplementation with insulin may not be accompanied by a reduction in adiponectin concentrations as insulin has already exerted its maximal inhibitory effect.

Only one study, Catalano et al. [23] determined the effect of insulin on adiponectin concentrations in a longitudinal study of lean pregnant women. Interestingly, the authors reported that insulin infusion decreased HMW adiponectin complexes in pregravid women but this suppressive effect of insulin was lost during pregnancy. The result of this study supports the report by Catalano et al. and extends it by demonstrating comparable maternal circulating adiponectin in patients with lean and overweight/obese patients with GDM. Congruent with this observation, we found no difference between patients who were treated with insulin and those who were managed with diet alone.

In conclusion, perturbation of adiponectin homeostasis and alterations in the relative distribution of its multimers are considered to be a marker of adipose tissue function since adiponectin is produced and modified exclusively by adipocytes. Evaluation of adiponectin isoforms in normal weight and overweight/obese patients with GDM reveals that this condition is characterized by a distinctive pattern of concentrations and a relative distribution of adiponectin multimers akin to Type 2 DM. Taken together, the results of the present study suggest that dysregulation of adiponectin multimers can provide a mechanistic basis for the association between adiposity and GDM. Moreover, the pattern of circulating adiponectin multimers concentrations and their relative abundance is congruent for both GDM and Type-2 DM. This finding suggests that adiponectin dysregulation can account for the long term complication of GDM. Further studies are needed in order to elucidate the intriguing relationships between adiponectin multimers, GDM and the subsequent development of Type 2 DM.

Acknowledgments

Supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS.

Reference List

1. Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech Rep Ser. 2003; 916:i–149. backcover. [PubMed: 12768890]
2. Gestational diabetes mellitus. Diabetes Care. 2004; 27 (Suppl 1):S88–S90. [PubMed: 14693936]
3. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2002; 25:202–212. [PubMed: 11772917]
4. Supplement 1. American Diabetes Association: clinical practice recommendations 2000. Diabetes Care. 2000; 23 (Suppl 1):S1–116. [PubMed: 10859117]
5. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol. 2001; 98:525–538. [PubMed: 11547793]
6. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979; 28:1039–1057. [PubMed: 510803]
7. Akcakus M, Koklu E, Baykan A, Yikilmaz A, Coskun A, Gunes T, et al. Macrosomic newborns of diabetic mothers are associated with increased aortic intima-media thickness and lipid concentrations. Horm Res. 2007; 67:277–283. [PubMed: 17191031]
8. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257:79–83. [PubMed: 10092513]
9. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes. 2006; 55:1954–1960. [PubMed: 16804063]
10. Ategbo JM, Grissa O, Yessoufou A, Hichami A, Dramane KL, Moutairou K, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab. 2006; 91:4137–4143. [PubMed: 16849405]
11. Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes. 2007; 56:2174–2177. [PubMed: 17513700]
12. Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet Med. 2004; 21:103–113. [PubMed: 14984444]
13. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001; 7:947–953. [PubMed: 11479628]
14. Bian X, Gao P, Xiong X, Xu H, Qian M, Liu S. Risk factors for development of diabetes mellitus in women with a history of gestational diabetes mellitus. Chin Med J(Engl). 2000; 113:759–762. [PubMed: 11776065]
15. Blumer RM, van der Crabben SN, Stegenga ME, Tanck MW, Ackermans MT, Endert E, et al. Hyperglycemia prevents the suppressive effect of hyperinsulinemia on plasma adiponectin levels in healthy humans. Am J Physiol Endocrinol Metab. 2008; 295:E613–E617. [PubMed: 18577692]
16. Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO, et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes. 2005; 54:2712–2719. [PubMed: 16123361]
17. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005; 115:e290–e296. [PubMed: 15741354]
18. Brame LA, Considine RV, Yamauchi M, Baron AD, Mather KJ. Insulin and endothelin in the acute regulation of adiponectin in vivo in humans. Obes Res. 2005; 13:582–588. [PubMed: 15833944]

19. Brankston GN, Mitchell BF, Ryan EA, Okun NB. Resistance exercise decreases the need for insulin in overweight women with gestational diabetes mellitus. *Am J Obstet Gynecol.* 2004; 190:188–193. [PubMed: 14749658]
20. Buchanan TA, Xiang AH. Gestational diabetes mellitus. *J Clin Invest.* 2005; 115:485–491. [PubMed: 15765129]
21. Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. *Diabetes Care.* 2007; 30 (Suppl 2):S246–S250. [PubMed: 17596480]
22. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. *Am J Obstet Gynecol.* 1982; 144:768–773. [PubMed: 7148898]
23. Catalano PM, Hoegh M, Minium J, Huston-Presley L, Bernard S, Kalhan S, et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. *Diabetologia.* 2006; 49:1677–1685. [PubMed: 16752186]
24. Catalano PM, Kirwan JP. Clinical utility and approaches for estimating insulin sensitivity in pregnancy. *Semin Perinatol.* 2002; 26:181–189. [PubMed: 12099307]
25. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. *Diabetes Care.* 2006; 29:2457–2461. [PubMed: 17065684]
26. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. *J Clin Invest.* 2001; 108:1875–1881. [PubMed: 11748271]
27. Cortelazzi D, Corbetta S, Ronzoni S, Pelle F, Marconi A, Cozzi V, et al. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. *Clin Endocrinol (Oxf).* 2007; 66:447–453. [PubMed: 17302882]
28. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *N Engl J Med.* 2005; 352:2477–2486. [PubMed: 15951574]
29. D'Anna R, Baviera G, Corrado F, Giordano D, De VA, Nicocia G, et al. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. *BJOG.* 2006; 113:1264–1269. [PubMed: 17010118]
30. Dabelea D, Pettitt DJ. Intrauterine diabetic environment confers risks for type 2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. *J Pediatr Endocrinol Metab.* 2001; 14:1085–1091. [PubMed: 11592564]
31. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. *Diabetes Care.* 2003; 26:2015–2020. [PubMed: 12832305]
32. Damm P. Gestational diabetes mellitus and subsequent development of overt diabetes mellitus. *Dan Med Bull.* 1998; 45:495–509. [PubMed: 9850811]
33. Dang K, Homko C, Reece EA. Factors associated with fetal macrosomia in offspring of gestational diabetic women. *J Matern Fetal Med.* 2000; 9:114–117. [PubMed: 10902825]
34. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. *Biochem Biophys Res Commun.* 2002; 290:1084–1089. [PubMed: 11798186]
35. Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, et al. Circulating high-molecular-weight adiponectin is upregulated in preeclampsia and is related to insulin sensitivity and renal function. *Eur J Endocrinol.* 2008; 158:197–201. [PubMed: 18230826]
36. Ferrara A, Kahn HS, Quesenberry CP, Riley C, Hedderson MM. An increase in the incidence of gestational diabetes mellitus: Northern California, 1991–2000. *Obstet Gynecol.* 2004; 103:526–533. [PubMed: 14990417]
37. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. *Diabetes.* 2002; 51:1131–1137. [PubMed: 11916936]
38. Filippi E, Sentinelli F, Trischitta V, Romeo S, Arca M, Leonetti F, et al. Association of the human adiponectin gene and insulin resistance. *Eur J Hum Genet.* 2004; 12:199–205. [PubMed: 14673476]

39. Fisher FF, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE, et al. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. *Diabetologia*. 2005; 48:1084–1087. [PubMed: 15902402]
40. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. *Proc Natl Acad Sci US A*. 2001; 98:2005–2010.
41. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, et al. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. *Clin Chim Acta*. 2004; 339:57–63. [PubMed: 14687894]
42. Gabbe SG. Gestational diabetes mellitus. *N Engl J Med*. 1986; 315:1025–1026. [PubMed: 3762606]
43. Girouard J, Giguere Y, Moutquin JM, Forest JC. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. *Hypertension*. 2007; 49:1056–1062. [PubMed: 17389257]
44. Gonzalez-Sanchez JL, Zabena CA, Martinez-Larrad MT, Fernandez-Perez C, Perez-Barba M, Laakso M, et al. An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance. *Obes Res*. 2005; 13:807–812. [PubMed: 15919831]
45. Greenberg LR, Moore TR, Murphy H. Gestational diabetes mellitus: antenatal variables as predictors of postpartum glucose intolerance. *Obstet Gynecol*. 1995; 86:97–101. [PubMed: 7784031]
46. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. *Diabetes*. 2002; 51:536–540. [PubMed: 11812766]
47. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. *Diabetes Care*. 2006; 29:1357–1362. [PubMed: 16732021]
48. Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA. Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. *Am J Physiol Endocrinol Metab*. 2006; 290:E326–E333. [PubMed: 16144822]
49. Hendler I, Blackwell SC, Mehta SH, Whitty JE, Russell E, Sorokin Y, et al. The levels of leptin, adiponectin, and resistin in normal weight, overweight, and obese pregnant women with and without preeclampsia. *Am J Obstet Gynecol*. 2005; 193:979–983. [PubMed: 16157097]
50. Hod M, Yogev Y. Goals of metabolic management of gestational diabetes: is it all about the sugar? *Diabetes Care*. 2007; 30 (Suppl 2):S180–S187. [PubMed: 17596469]
51. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol*. 2000; 20:1595–1599. [PubMed: 10845877]
52. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. *J Biol Chem*. 1996; 271:10697–10703. [PubMed: 8631877]
53. Hu FB, Doria A, Li T, Meigs JB, Liu S, Memisoglu A, et al. Genetic variation at the adiponectin locus and risk of type 2 diabetes in women. *Diabetes*. 2004; 53:209–213. [PubMed: 14693717]
54. Innes KE, Wimsatt JH, McDuffie R. Relative glucose tolerance and subsequent development of hypertension in pregnancy. *Obstet Gynecol*. 2001; 97:905–910. [PubMed: 11384694]
55. Joffe GM, Esterlitz JR, Levine RJ, Clemens JD, Ewell MG, Sibai BM, et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. *Am J Obstet Gynecol*. 1998; 179:1032–1037. [PubMed: 9790393]
56. Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. *Am J Obstet Gynecol*. 1989; 161:415–419. [PubMed: 2764059]
57. Kajantie E, Kaaja R, Ylikorkala O, Andersson S, Laivuori H. Adiponectin concentrations in maternal serum: elevated in preeclampsia but unrelated to insulin sensitivity. *J Soc Gynecol Invest*. 2005; 12:433–439.

58. Katsuki A, Suematsu M, Gabazza EC, Murashima S, Nakatani K, Togashi K, et al. Decreased high-molecular weight adiponectin-to-total adiponectin ratio in sera is associated with insulin resistance in Japanese metabolically obese, normal-weight men with normal glucose tolerance. *Diabetes Care*. 2006; 29:2327–2328. [PubMed: 17003319]
59. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab*. 2004; 89:2548–2556. [PubMed: 15181022]
60. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care*. 2002; 25:1862–1868. [PubMed: 12351492]
61. Kim MJ, Yoo KH, Park HS, Chung SM, Jin CJ, Lee Y, et al. Plasma adiponectin and insulin resistance in Korean type 2 diabetes mellitus. *Yonsei Med J*. 2005; 46:42–50. [PubMed: 15744804]
62. Kinalski M, Telejko B, Kuzmicki M, Kretowski A, Kinalska I. Tumor necrosis factor alpha system and plasma adiponectin concentration in women with gestational diabetes. *Horm Metab Res*. 2005; 37:450–454. [PubMed: 16034719]
63. Kjos SL, Buchanan TA, Greenspoon JS, Montoro M, Bernstein GS, Mestman JH. Gestational diabetes mellitus: the prevalence of glucose intolerance and diabetes mellitus in the first two months post partum. *Am J Obstet Gynecol*. 1990; 163:93–98. [PubMed: 2375376]
64. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. *Circ Res*. 2004; 94:e27–e31. [PubMed: 14752031]
65. Kusanovic JP, Romero R, Mazaki-Tovi S, Chaiworapongsa T, Mittal P, Gotsch F, et al. Resistin in Amniotic Fluid and its Association with Intra-amniotic Infection and Inflammation. *The Journal of Maternal-Fetal and Neonatal Medicine*. 2008
66. Langer O, Anyaegbunam A, Brustman L, Divon M. Management of women with one abnormal oral glucose tolerance test value reduces adverse outcome in pregnancy. *Am J Obstet Gynecol*. 1989; 161:593–599. [PubMed: 2675597]
67. Langer O, Anyaegbunam A, Brustman L, Guidetti D, Mazze R. Gestational diabetes: insulin requirements in pregnancy. *Am J Obstet Gynecol*. 1987; 157:669–675. [PubMed: 3307425]
68. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. *N Engl J Med*. 2000; 343:1134–1138. [PubMed: 11036118]
69. Langer O, Mazze R. The relationship between large-for-gestational-age infants and glycemic control in women with gestational diabetes. *Am J Obstet Gynecol*. 1988; 159:1478–1483. [PubMed: 3207126]
70. Lee CJ, Hsieh TT, Chiu TH, Chen KC, Lo LM, Hung TH. Risk factors for pre-eclampsia in an Asian population. *Int J Gynaecol Obstet*. 2000; 70:327–333. [PubMed: 10967166]
71. Lee YY, Lee NS, Cho YM, Moon MK, Jung HS, Park YJ, et al. Genetic association study of adiponectin polymorphisms with risk of Type 2 diabetes mellitus in Korean population. *Diabet Med*. 2005; 22:569–575. [PubMed: 15842511]
72. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. *Lancet*. 2002; 360:57–58. [PubMed: 12114044]
73. Lu D, Yang X, Wu Y, Wang H, Huang H, Dong M. Serum adiponectin, leptin and soluble leptin receptor in pre-eclampsia. *Int J Gynaecol Obstet*. 2006; 95:121–126. [PubMed: 16919629]
74. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). *Biochem Biophys Res Commun*. 1996; 221:286–289. [PubMed: 8619847]
75. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. *Nat Med*. 2002; 8:731–737. [PubMed: 12068289]
76. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. *Diabetes*. 2001; 50:2094–2099. [PubMed: 11522676]

77. Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Gotsch F, et al. Maternal Serum Adiponectin Multimers in Preeclampsia. *Journal of Perinatal Medicine*. 2009; 37(4):349–363. [PubMed: 19348608]
78. Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, Than GN, et al. Maternal visfatin concentration in normal pregnancy. *Journal of Perinatal Medicine*. 2009; 37:206–217. [PubMed: 19284295]
79. Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, Than GN, et al. Visfatin in human pregnancy: maternal gestational diabetes vis-a-vis neonatal birthweight. *Journal Of Perinatal Medicine*. 2009; 37:218–231. [PubMed: 19099366]
80. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Efraty Y, Schiff E, et al. Determining the source of fetal adiponectin. *J Reprod Med*. 2007; 52:774–778. [PubMed: 17939592]
81. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Schiff E, Sivan E. Cord blood adiponectin in large-for-gestational age newborns. *Am J Obstet Gynecol*. 2005; 193:1238–1242. [PubMed: 16157144]
82. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Wiser A, Schiff E, et al. Maternal serum adiponectin levels during human pregnancy. *J Perinatol*. 2007; 27:77–81. [PubMed: 17262038]
83. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Yinon Y, Wiser A, et al. Adiponectin and leptin concentrations in dichorionic twins with discordant and concordant growth. *J Clin Endocrinol Metab*. 2009; 94:892–898. [PubMed: 19066299]
84. Mazaki-Tovi S, Kanety H, Sivan E. Adiponectin and human pregnancy. *Curr Diab Rep*. 2005; 5:278–281. [PubMed: 16033679]
85. Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, Mittal P, et al. Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition. *J Perinat Med*. 2009; 36:485–496. [PubMed: 18598235]
86. Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Vaisbuch E, Gotsch F, et al. Adiponectin multimers in maternal plasma. *J Matern Fetal Neonatal Med*. 2008; 21:796–815. [PubMed: 19031276]
87. McLachlan KA, O'Neal D, Jenkins A, Alford FP. Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. *Diabetes Metab Res Rev*. 2006; 22:131–138. [PubMed: 16170833]
88. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. *J Clin Endocrinol Metab*. 2003; 88:6098–6106. [PubMed: 14671216]
89. Menzaghi C, Coco A, Salvemini L, Thompson R, De CS, Doria A, et al. Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. *J Clin Endocrinol Metab*. 2006; 91:2792–2795. [PubMed: 16670163]
90. Menzaghi C, Ercolino T, Di PR, Berg AH, Warram JH, Scherer PE, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. *Diabetes*. 2002; 51:2306–2312. [PubMed: 12086965]
91. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. *Diabetes Care*. 1998; 21 (Suppl 2):B161–B167. [PubMed: 9704245]
92. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus. *Diabetes Res Clin Pract*. 2001; 52:119–123. [PubMed: 11311966]
93. Mohlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF, et al. Insulin decreases human adiponectin plasma levels. *Horm Metab Res*. 2002; 34:655–658. [PubMed: 12660877]
94. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. *J Biochem (Tokyo)*. 1996; 120:803–812. [PubMed: 8947845]
95. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2

- diabetes in Japanese-Americans. *J Clin Endocrinol Metab.* 2006; 91:3873–3877. [PubMed: 16882743]
96. Nakatani K, Noma K, Nishioka J, Kasai Y, Morioka K, Katsuki A, et al. Adiponectin gene variation associates with the increasing risk of type 2 diabetes in non-diabetic Japanese subjects. *Int J Mol Med.* 2005; 15:173–177. [PubMed: 15583845]
 97. Naruse K, Yamasaki M, Umekage H, Sado T, Sakamoto Y, Morikawa H. Peripheral blood concentrations of adiponectin, an adipocyte-specific plasma protein, in normal pregnancy and preeclampsia. *J Reprod Immunol.* 2005; 65:65–75. [PubMed: 15694968]
 98. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. *J Biol Chem.* 2006; 281:2654–2660. [PubMed: 16326714]
 99. Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, et al. Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. *J Perinat Med.* 2007; 35:522–531. [PubMed: 17919116]
 100. Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, et al. Adiponectin in severe preeclampsia. *J Perinat Med.* 2007; 35:503–512. [PubMed: 17919115]
 101. Nien JK, Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, et al. Resistin: a hormone which induces insulin resistance is increased in normal pregnancy. *J Perinat Med.* 2007; 35:513–521. [PubMed: 17919114]
 102. O'Sullivan JB, MAHAN CM. CRITERIA FOR THE ORAL GLUCOSE TOLERANCE TEST IN PREGNANCY. *Diabetes.* 1964; 13:278–285. [PubMed: 14166677]
 103. Ong GK, Hamilton JK, Sermer M, Connelly PW, Maguire G, Zinman B, et al. Maternal serum adiponectin and infant birthweight: the role of adiponectin isoform distribution. *Clin Endocrinol (Oxf).* 2007; 67:108–114. [PubMed: 17466005]
 104. Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, et al. The G/G genotype of a resistin single-nucleotide polymorphism at –420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. *Am J Hum Genet.* 2004; 75:678–686. [PubMed: 15338456]
 105. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. *J Biol Chem.* 2003; 278:9073–9085. [PubMed: 12496257]
 106. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. *J Biol Chem.* 2004; 279:12152–12162. [PubMed: 14699128]
 107. Peake PW, Kriketos AD, Campbell LV, Shen Y, Charlesworth JA. The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. *Eur J Endocrinol.* 2005; 153:409–417. [PubMed: 16131604]
 108. Persson B, Hanson U. Neonatal morbidities in gestational diabetes mellitus. *Diabetes Care.* 1998; 21 (Suppl 2):B79–B84. [PubMed: 9704232]
 109. Peters RK, Kjos SL, Xiang A, Buchanan TA. Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus. *Lancet.* 1996; 347:227–230. [PubMed: 8551882]
 110. Plagemann A, Harder T, Kohlhoff R, Rohde W, Dorner G. Overweight and obesity in infants of mothers with long-term insulin-dependent diabetes or gestational diabetes. *Int J Obes Relat Metab Disord.* 1997; 21:451–456. [PubMed: 9192228]
 111. Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI. Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. *Metabolism.* 2004; 53:1454–1461. [PubMed: 15536601]
 112. Qi L, Doria A, Giorgi E, Hu FB. Variations in adiponectin receptor genes and susceptibility to type 2 diabetes in women: a tagging-single nucleotide polymorphism haplotype analysis. *Diabetes.* 2007; 56(6):1586–91. [PubMed: 17416799]
 113. Ramsay JE, Jamieson N, Greer IA, Sattar N. Paradoxical elevation in adiponectin concentrations in women with preeclampsia. *Hypertension.* 2003; 42:891–894. [PubMed: 14517227]

114. Ranheim T, Haugen F, Staff AC, Braekke K, Harsem NK, Drevon CA. Adiponectin is reduced in gestational diabetes mellitus in normal weight women. *Acta Obstet Gynecol Scand.* 2004; 83:341–347. [PubMed: 15005780]
115. Retnakaran R, Connelly PW, Maguire G, Sermer M, Zinman B, Hanley AJ. Decreased high-molecular-weight adiponectin in gestational diabetes: implications for the pathophysiology of Type 2 diabetes. *Diabet Med.* 2007; 24:245–252. [PubMed: 17305786]
116. Retnakaran R, Hanley AJ, Connelly PW, Maguire G, Sermer M, Zinman B. Low serum levels of high-molecular weight adiponectin in Indo-Asian women during pregnancy: evidence of ethnic variation in adiponectin isoform distribution. *Diabetes Care.* 2006; 29:1377–1379. [PubMed: 16732024]
117. Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. *Diabetes Care.* 2004; 27:799–800. [PubMed: 14988306]
118. Retnakaran R, Hanley AJ, Raif N, Hirning CR, Connelly PW, Sermer M, et al. Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications. *Diabetologia.* 2005; 48:993–1001. [PubMed: 15778860]
119. Roberts R. Hypertension in women with gestational diabetes. *Diabetes Care.* 1998; 21 (Suppl 2):B27–B32. [PubMed: 9704224]
120. Ros HS, Cnattingius S, Lipworth L. Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study. *Am J Epidemiol.* 1998; 147:1062–1070. [PubMed: 9620050]
121. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. *N Engl J Med.* 2008; 358:2003–2015. [PubMed: 18463376]
122. Sacks DA, Greenspoon JS, bu-Fadil S, Henry HM, Wolde-Tsadik G, Yao JF. Toward universal criteria for gestational diabetes: the 75-gram glucose tolerance test in pregnancy. *Am J Obstet Gynecol.* 1995; 172:607–614. [PubMed: 7856693]
123. Salopuro T, Pulkkinen L, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, et al. Genetic variation in leptin receptor gene is associated with type 2 diabetes and body weight: The Finnish Diabetes Prevention Study. *Int J Obes (Lond).* 2005; 29:1245–1251. [PubMed: 15997246]
124. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? *BMJ.* 2002; 325:157–160. [PubMed: 12130616]
125. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J Biol Chem.* 1995; 270:26746–26749. [PubMed: 7592907]
126. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. *Diabetes Care.* 2004; 27:1680–1687. [PubMed: 15220246]
127. Sermer M, Naylor CD, Gare DJ, Kenshole AB, Ritchie JW, Farine D, et al. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. *Am J Obstet Gynecol.* 1995; 173:146–156. [PubMed: 7631672]
128. Sivan E, Mazaki-Tovi S, Pariente C, Efraty Y, Schiff E, Hemi R, et al. Adiponectin in human cord blood: relation to fetal birth weight and gender. *J Clin Endocrinol Metab.* 2003; 88:5656–5660. [PubMed: 14671149]
129. Solomon CG, Seely EW. Brief review: hypertension in pregnancy : a manifestation of the insulin resistance syndrome? *Hypertension.* 2001; 37:232–239. [PubMed: 11230277]
130. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. *Lancet.* 2003; 361:226–228. [PubMed: 12547549]
131. Stumvoll M, Tschrirter O, Fritsche A, Staiger H, Renn W, Weisser M, et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. *Diabetes.* 2002; 51:37–41. [PubMed: 11756320]
132. Takemura Y, Osuga Y, Koga K, Tajima T, Hirota Y, Hirata T, et al. Selective increase in high molecular weight adiponectin concentration in serum of women with preeclampsia. *J Reprod Immunol.* 2007; 73:60–65. [PubMed: 16860876]

133. Tasanen K, Eble JA, Aumailley M, Schumann H, Baetge J, Tu H, et al. Collagen XVII is destabilized by a glycine substitution mutation in the cell adhesion domain Col15. *J Biol Chem.* 2000; 275:3093–3099. [PubMed: 10652291]
134. Thyfault JP, Hedberg EM, Anchan RM, Thorne OP, Isler CM, Newton ER, et al. Gestational diabetes is associated with depressed adiponectin levels. *J Soc Gynecol Investig.* 2005; 12:41–45.
135. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. *Proc Natl Acad Sci US A.* 2002; 99:16309–16313.
136. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. *Diabetes.* 2004; 53:1621–1629. [PubMed: 15161771]
137. Tsai PJ, Yu CH, Hsu SP, Lee YH, Huang IT, Ho SC, et al. Maternal plasma adiponectin concentrations at 24 to 31 weeks of gestation: negative association with gestational diabetes mellitus. *Nutrition.* 2005; 21:1095–1099. [PubMed: 16308131]
138. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). *J Biol Chem.* 2002; 277:29359–29362. [PubMed: 12087086]
139. Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. *J Biol Chem.* 2003; 278:50810–50817. [PubMed: 14522956]
140. Tuffnell DJ, West J, Walkinshaw SA. Treatments for gestational diabetes and impaired glucose tolerance in pregnancy. *Cochrane Database Syst Rev.* 2003; CD003395, 1–38. [PubMed: 12917965]
141. Vaisbuch E, Mazaki-Tovi S, Kusanovic JP, Erez O, Than GN, Kim SK, et al. Retinol Binding Protein 4: An Adipokine Associated with Intra-amniotic Infection / Inflammation. *J Matern Fetal Neonatal Med.* 2009 In Press.
142. Vasseur F, Lepretre F, Lacquemant C, Froguel P. The genetics of adiponectin. *Curr Diab Rep.* 2003; 3:151–158. [PubMed: 12728641]
143. Vidaeff AC, Yeomans ER, Ramin SM. Gestational diabetes: a field of controversy. *Obstet Gynecol Surv.* 2003; 58:759–769. [PubMed: 14581827]
144. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. *J Biol Chem.* 2003; 278:40352–40363. [PubMed: 12878598]
145. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab.* 2001; 86:1930–1935. [PubMed: 11344187]
146. Williams MA, Qiu C, Muiy-Rivera M, Vadachkoria S, Song T, Luthy DA. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. *J Clin Endocrinol Metab.* 2004; 89:2306–2311. [PubMed: 15126557]
147. Worda C, Leipold H, Gruber C, Kautzky-Willer A, Knofler M, Bancher-Todesca D. Decreased plasma adiponectin concentrations in women with gestational diabetes mellitus. *Am J Obstet Gynecol.* 2004; 191:2120–2124. [PubMed: 15592301]
148. Xiong X, Saunders LD, Wang FL, Demianczuk NN. Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes. *Int J Gynaecol Obstet.* 2001; 75:221–228. [PubMed: 11728481]
149. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat Med.* 2001; 7:941–946. [PubMed: 11479627]
150. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature.* 2005; 436:356–362. [PubMed: 16034410]
151. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody

are elevated in individuals with type 2 diabetes mellitus. *J Clin Endocrinol Metab.* 2004; 89:150–156. [PubMed: 14715842]

152. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. *Diabetes.* 2002; 51:2968–2974. [PubMed: 12351435]
153. Zhang YY, Gottardo L, Thompson R, Powers C, Nolan D, Duffy J, et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. *Obesity*(Silver Spring). 2006; 14:2119–2126. [PubMed: 17189536]

Figure 1. Comparison of the median serum total, HMW, MMW and LMW adiponectin concentrations between pregnant women with normal pregnancies and those with GDM
The median maternal serum concentration of total, HMW, MMW and LMW were significantly lower in patients with GDM than in those with normal pregnancies ($p < 0.001$ for all comparisons)

Figure 2. Comparison of HMW/Total adiponectin MMW/Total adiponectin and LMW/Total adiponectin ratios between pregnant women with normal pregnancies and those with GDM
 The median maternal HMW/Total adiponectin ratio was lower in patients with GDM than in those with a normal pregnancy. In contrast, patients with GDM had a higher median MMW/Total adiponectin and LMW/Total adiponectin ratios than those with a normal pregnancy.

Figure 3A

Figure 3B

Figure 3C

Figure 3D

Figure 3. Maternal serum total adiponectin (A), HMW adiponectin (B), MMW adiponectin (C) and LMW adiponectin (D) concentrations in women with a normal pregnancy and those with GDM according to first trimester BMI (normal weight vs. overweight/obese)

Among patients with a normal pregnancy, the median serum concentration of total and HMW adiponectin were higher in women with normal weight than in those with overweight/obesity. Among patients with GDM, women with normal weight and those with overweight/obesity did not differ in the median serum concentrations of total, HMW, MMW and LMW adiponectin. Among patients with overweight/obesity, women with a normal pregnancy had higher median serum concentrations of total, HMW, MMW and LMW adiponectin ($p=0.020$) than those with GDM.

Figure 4A

Figure 4B

Figure 4C

Figure 4. Comparison of HMW/Total adiponectin (A) MMW/Total adiponectin (B) and LMW/Total adiponectin (C) ratios between in women with a normal pregnancy and those with GDM according to first trimester BMI (normal weight vs. overweight/obese)

Women with normal weight and those with overweight/obesity did not differ in the median ratio of HMW/Total adiponectin, MMW/Total adiponectin and LMW/Total adiponectin. Similarly, among patients with GDM, these ratios were comparable between patients with

normal weight and those with overweight/obesity. Overweight/obese women with a normal pregnancy had a higher HMW/Total adiponectin ratio than those with GDM. In contrast, the MMW/Total adiponectin and LMW/Total adiponectin ratios were lower in overweight/obese pregnant women with a normal pregnancy than in those with GDM.

Table 1

Clinical and demographic characteristics of the study population

	Normal Pregnancy (n=149)	Gestational Diabetes Mellitus (n=72)	p
Maternal age (years)	25.0 (21.0–31.0)	27.0 (23.0–33.0)	0.1
Ethnic origin			
African American	58 (80.6%)	110 (73.8%)	0.1
Hispanic	8 (11.1)	29 (19.5%)	0.2
Caucasian	4 (5.5%)	8 (5.3%)	0.9
Others	2 (2.7%)	2 (1.3%)	0.4
First trimester BMI (kg/m²)	24.0 (22.0–26.2)	30.6 (24.5–36.6)	<0.001
BMI at blood sampling (kg/m²)	30.0 (27.7–33.3)	35.3 (29.8–41.5)	<0.001
BMI difference between blood sampling and the first trimester	5.6 (4.4–7.2)	4.5 (3.0–6.1)	0.3
Gestational age at sampling (weeks)	37.6 (32.8–40.2)	37.6 (33.4–39.0)	0.1
Gestational age at delivery (weeks)	39.8 (39.0–40.2)	38.2 (36.8–39.2)	0.07
Birth weight (g)	3285 (2862–3687)	3440 (3210–3670)	0.018

Values are expressed as median (interquartile range); NS: Not significant; BMI: Body Mass Index

Table 2
Clinical and demographic characteristics of the study population according to body mass index

	Normal Pregnancy		p	Gestational Diabetes Mellitus		p
	Normal Weight (n=94)	Overweight/Obese (n=55)		Normal Weight (n=24)	Overweight/Obese (n=48)	
Maternal age (years)	25.0 (20.7–30.0)	28.0 (22.0–33.0)	0.07	27.0 (20.5–32.2)	27.0 (23.0–33.7)	0.7
First trimester BMI (kg/m ²)	22.5 (21.3–23.7)	27.0 (25.8–29.2)	<0.01	23.7 (20.5–24.7)	33.2 (30.6–41.9)	<0.01
BMI at blood sampling (kg/m ²)	28.4 (26.7–30.1)	33.3 (30.7–35.0)	<0.01	28.9 (25.2–30.5)	40.3 (35.0–45.5)	<0.01
BMI difference between sampling and the first trimester	5.8 (4.7–7.4)	5.1 (3.6–6.5)	0.3	5.1 (3.7–6.4)	4.1 (2.7–5.9)	0.6
Gestational age at sampling (weeks)	38.1 (32.7–40.4)	33.7 (32.7–40.1)	0.2	37.1 (32.8–39.1)	37.6 (34.0–38.9)	0.9
Gestational age at delivery (weeks)	39.9 (39.0–40.2)	39.7 (38.8–40.7)	0.8	37.3 (36.7–39.2)	38.3 (36.6–39.1)	0.3
Birth weight (g)	3145 (2458–3772)	3335 (2875–3595)	0.4	3405 (3197–3690)	3500 (3230–3670)	0.5